Literature DB >> 10570158

Transcriptional regulation of the rat Müllerian inhibiting substance type II receptor in rodent Leydig cells.

J Teixeira1, D J Kehas, R Antun, P K Donahoe.   

Abstract

Müllerian inhibiting substance (MIS) causes regression of the fetal Müllerian duct on binding a heteromeric complex of types I and II cell-surface receptors in the fetal urogenital ridge. The MIS type II receptor (MISRII), which provides specificity for MIS, is also expressed in the adult testis, ovary, and uterus. The rat MISRII promoter was cloned to study the molecular mechanisms underlying its temporal and cell-specific expression. The 1.6-kilobase (kb) promoter contained no recognizable TATA or CAAT box, but there was a consensus Sp1 site upstream of the transcription initiation site. Two binding sites for the orphan nuclear receptor steroidogenic factor-1 (SF-1) are occupied in vitro by using nuclear extracts from R2C cells, an MIS-responsive rat Leydig cell line that expresses endogenous MISRII, with differing affinities, indicating that the distal SF-1 site is bound more avidly than is the proximal SF-1 site. R2C cells transfected with MISRII promoter/luciferase reporter constructs show a 12-fold induction with the 1.6-kb fragment and deletion of sequences upstream of -282-bp lowered luciferase expression to one-third. Mutation of both SF-1 sites greatly inhibited luciferase expression, whereas mutation of either site alone resulted in continuing activation by endogenous SF-1, indicating redundancy. In vitro binding and transcriptional analyses suggest that a proximal potential Smad-responsive element and an uncharacterized element also contribute to activation of the MISRII gene. R2C cells and MISRII promoter regulation can now be used to uncover endogenous transcription factors responsible for receptor expression or repression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10570158      PMCID: PMC24150          DOI: 10.1073/pnas.96.24.13831

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  Cloning by recognition site screening of two novel GT box binding proteins: a family of Sp1 related genes.

Authors:  G Hagen; S Müller; M Beato; G Suske
Journal:  Nucleic Acids Res       Date:  1992-11-11       Impact factor: 16.971

2.  Mechanism of transcriptional activation by Sp1: evidence for coactivators.

Authors:  B F Pugh; R Tjian
Journal:  Cell       Date:  1990-06-29       Impact factor: 41.582

3.  Familial incomplete male pseudohermaphroditism, type 1. Evidence for androgen resistance and variable clinical manifestations in a family with the Reifenstein syndrome.

Authors:  J D Wilson; M J Harrod; J L Goldstein; D L Hemsell; P C MacDonald
Journal:  N Engl J Med       Date:  1974-05-16       Impact factor: 91.245

Review 4.  Anti-müllerian hormone: the Jost factor.

Authors:  N Josso; R L Cate; J Y Picard; B Vigier; N di Clemente; C Wilson; S Imbeaud; R B Pepinsky; D Guerrier; L Boussin
Journal:  Recent Prog Horm Res       Date:  1993

5.  Müllerian-inhibiting substance regulates androgen synthesis at the transcriptional level.

Authors:  J Teixeira; E Fynn-Thompson; A H Payne; P K Donahoe
Journal:  Endocrinology       Date:  1999-10       Impact factor: 4.736

6.  Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei.

Authors:  J D Dignam; R M Lebovitz; R G Roeder
Journal:  Nucleic Acids Res       Date:  1983-03-11       Impact factor: 16.971

7.  Abnormal sexual development in transgenic mice chronically expressing müllerian inhibiting substance.

Authors:  R R Behringer; R L Cate; G J Froelick; R D Palmiter; R L Brinster
Journal:  Nature       Date:  1990-05-10       Impact factor: 49.962

8.  Transcription from a TATA-less promoter requires a multisubunit TFIID complex.

Authors:  B F Pugh; R Tjian
Journal:  Genes Dev       Date:  1991-11       Impact factor: 11.361

9.  SRY recognizes conserved DNA sites in sex-specific promoters.

Authors:  C M Haqq; C Y King; P K Donahoe; M A Weiss
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-01       Impact factor: 11.205

10.  Isolation of the bovine and human genes for Müllerian inhibiting substance and expression of the human gene in animal cells.

Authors:  R L Cate; R J Mattaliano; C Hession; R Tizard; N M Farber; A Cheung; E G Ninfa; A Z Frey; D J Gash; E P Chow
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

View more
  10 in total

1.  An alternative promoter of the human neuronal nitric oxide synthase gene is expressed specifically in Leydig cells.

Authors:  Yang Wang; Derek C Newton; Tricia L Miller; Anouk-Martine Teichert; M James Phillips; Michail S Davidoff; Philip A Marsden
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

2.  Endogenous expression of Müllerian inhibiting substance in early postnatal rat sertoli cells requires multiple steroidogenic factor-1 and GATA-4-binding sites.

Authors:  K Watanabe; T R Clarke; A H Lane; X Wang; P K Donahoe
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

3.  Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.

Authors:  Rafael Pieretti-Vanmarcke; Patricia K Donahoe; Lisa A Pearsall; Daniela M Dinulescu; Denise C Connolly; Elkan F Halpern; Michael V Seiden; David T MacLaughlin
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-06       Impact factor: 11.205

4.  Novel Targets for the Transcription Factors MEF2 in MA-10 Leydig Cells.

Authors:  Mickaël Di-Luoffo; Caroline Daems; Francis Bergeron; Jacques J Tremblay
Journal:  Biol Reprod       Date:  2015-05-27       Impact factor: 4.285

5.  A role for BRCA1 in uterine leiomyosarcoma.

Authors:  Deyin Xing; George Scangas; Mai Nitta; Lei He; Xuan Xu; Yevgeniya J M Ioffe; Paul-Joseph Aspuria; Cyrus Y Hedvat; Matthew L Anderson; Esther Oliva; Beth Y Karlan; Gayatry Mohapatra; Sandra Orsulic
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

6.  The anti-Müllerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligand.

Authors:  Imed Salhi; Sylvie Cambon-Roques; Isabelle Lamarre; Daniel Laune; Franck Molina; Martine Pugnière; Didier Pourquier; Marian Gutowski; Jean-Yves Picard; Françoise Xavier; André Pèlegrin; Isabelle Navarro-Teulon
Journal:  Biochem J       Date:  2004-05-01       Impact factor: 3.857

7.  Wilms' tumor protein Wt1 is an activator of the anti-Müllerian hormone receptor gene Amhr2.

Authors:  Jürgen Klattig; Ralph Sierig; Dagmar Kruspe; Birgit Besenbeck; Christoph Englert
Journal:  Mol Cell Biol       Date:  2007-04-09       Impact factor: 4.272

Review 8.  Transcription Factors in the Regulation of Leydig Cell Gene Expression and Function.

Authors:  Karine de Mattos; Robert S Viger; Jacques J Tremblay
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-07       Impact factor: 6.055

9.  The Nuclear Receptor COUP-TFII Regulates Amhr2 Gene Transcription via a GC-Rich Promoter Element in Mouse Leydig Cells.

Authors:  Samir Mehanovic; Raifish E Mendoza-Villarroel; Robert S Viger; Jacques J Tremblay
Journal:  J Endocr Soc       Date:  2019-10-01

10.  Identification of novel genes and pathways regulated by the orphan nuclear receptor COUP-TFII in mouse MA-10 Leydig cells†.

Authors:  Samir Mehanovic; Raifish E Mendoza-Villarroel; Karine de Mattos; Philippe Talbot; Robert S Viger; Jacques J Tremblay
Journal:  Biol Reprod       Date:  2021-11-15       Impact factor: 4.161

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.